What is RUO - research use only

New Post Public Reply Private Reply Replies (0) Message Board
jpetroinc
What is RUO - research use only devices

http://www.insidemedicaldevices.com/2013/12/2...-products/

FDA Issues Final Guidance Regarding Research Use Only and Investigational Use Only Products

By Saurabh Anand on December 20th, 2013

On November 25, 2013, FDA issued a final guidance on research use only (RUO) and investigational use only (IUO) products. FDA describes RUO products as devices in the laboratory phase of development and IUO products as devices in the product testing phase of development. RUO products also may be offered and promoted for non-clinical purposes, such as basic research activities.

The final guidance characterizes RUO and IUO labeling “as a warning, to prevent such products from being used in clinical diagnosis, patient management, or human clinical trials that are not exempt from 21 C.F.R. part 812” requirements. FDA expresses concern that improperly labeling products as RUO or IUO might lead to “clinical diagnostic use of products with unproven performance characteristics and with manufacturing controls that are inadequate to ensure consistent manufacturing of the finished product.”

The final guidance provides FDA’s current thinking on when products are properly labeled and distributed as RUO and IUO products and includes some significant differences from a draft guidance issued in June 2011.

As we previously discussed, and as other stakeholders noted (see, for example, this letter from Members of Congress to the Commissioner of Food and Drugs and a news article here), the draft guidance departed from the general principle that FDA determines a product’s intended use through the manufacturer’s representations. Specifically, the draft guidance stated that a manufacturer that “knows, or has reason to know” of a customer’s inappropriate uses of an RUO/IUO product should halt sales to the customer or comply with premarket review requirements.

The final guidance abandons these positions. Instead, the final guidance states that FDA will consider a manufacturer’s “overt expressions,” as well as product design and “how the device is sold and distributed by or on behalf of the manufacturer,” to determine whether the product is properly labeled RUO or IUO. The final guidance also provides the following examples of evidence that would appear to conflict with RUO or IUO labeling, “depending on the totality of the circumstances”:

•Written or verbal statements suggesting the product may be used for clinical diagnostic use. FDA may consider the manufacturer’s statements in labeling, advertising, or promotion, including any performance claims, instructions for clinical interpretation, clinical information product names, workshops, or presentations. For example, in FDA’s view, instructions for an RUO product that discuss clinical significance of test results are evidence of intent to market the product for clinical diagnostic purposes.

•Written or verbal statements suggesting that clinical laboratories can validate the test through their own procedures and offer it for clinical diagnostic use as a laboratory developed test. FDA may find that a manufacturer of an RUO-labeled product intends for the product to be used in clinical applications if its sales force makes routine calls to clinical laboratories that do not perform research or clinical studies.

•Provision of specialized technical support to clinical laboratories. FDA does not consider support services such as general repair or maintenance, or general software updates, as evidence of non-research or non-investigational intended use. But FDA would consider, for example, a manufacturer’s assistance to a lab in validating or verifying a clinical diagnostic assay that uses the RUO or IUO product as evidence of the manufacturer’s intended use.

•Other relevant practices. Though not determinative, FDA stated it would consider whether a product was previously intended for clinical diagnostic use as an analyte specific reagent (ASR) and then labeled RUO or IUO without any change in its distribution practices. According to FDA, “the ‘new’ RUO/IUO labeling is likely to be inconsistent with the intended use of the manufacturer” in these situations.

The final guidance also takes a different approach to “certification programs” than both the draft guidance and FDA’s 1998 draft compliance policy guide (CPG) on RUO and IUO products. Pursuant to these programs, users of RUO and IUO products could certify to the manufacturer that they will not use products in a manner inconsistent with labeling. The draft guidance did not mention such programs, although the 1998 CPG stated that a firm with a certification program “is likely to be able to provide FDA with documentation to establish that a particular IVD labeled [RUO or IUO] . . . is not being commercialized for diagnostic or prognostic use.” Unlike the draft guidance, the final guidance mentions certification programs, but it appears to assign less weight to them than the 1998 CPG. Namely, the final guidance states that such programs “would be viewed as one factor to consider” in determining a manufacturer’s intended use and “would not relieve manufacturers from their responsibilities to ensure that their labeling and distribution practices for RUO/IUO products are consistent with the product’s RUO/IUO label.”

Although some have suggested that the final guidance portends increased enforcement efforts in this area, it is too soon tell. Also, a bill regarding FDA’s authority over RUO products was introduced in August and, if enacted, would affect the RUO landscape. Under the bill, FDA could not deem an RUO product misbranded because the manufacturer or distributor engaged in certain business communications (including technical support and customer service) with the user or sold to end users that used the product in a manner inconsistent with its labeling.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 84

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 69

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 74

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading

Top 5 Most Recently Viewed Articles

American Teachers Alliance Initiates Empowering Programs for Students

Updated Category News Views 143

Empowering Future Educators with College Chapters In a progressive move to inspire and support the upcoming generation of teachers, the American Teachers Alliance (ATA) has launched a significant initiative aimed at engaging college students across universities. This initiative introduces college student chapters, fostering a community where aspiring educators can enhance...

Continue Reading
Enhancing Enterprise Collaboration: Progress ShareFile and Microsoft 365

Updated Category News Views 190

Introduction to Progress ShareFile's New Features Progress, a leading provider of AI-driven digital experience and infrastructure software, is excited to announce significant advancements to its ShareFile platform. The recent updates mark a transformative leap in how enterprises collaborate using Microsoft 365, empowering teams to work more securely and efficiently. Deep...

Continue Reading
Shareholder Alert: Investigations on Major Mergers for 2025

Updated Category News Views 314

Investigating Significant Mergers in 2025 In the financial landscape, the merging of companies can significantly impact shareholders. Recognizing the importance of every shareholder's voice, we delve into several notable mergers that are under scrutiny as we approach votes critical to shareholders. As many companies opt for merger routes, understanding the implications of...

Continue Reading
Explore the Vibrant Daylight Shows Series in NYC's Hotspots

Updated Category News Views 181

Unveiling the Daylight Shows at Daylight Studio Experience the vibrant world of creativity at Daylight Studio, a prominent event venue nestled in two of New York City's most dynamic areas, Hudson Yards and Flatiron. With years of experience in supporting film, fashion, and artistic endeavors, Daylight Studio has secured its place as a go-to location for creatives and...

Continue Reading
Ventyx Biosciences Begins Phase 2a Trial for Parkinson’s Treatment

Updated Category News Views 138

Ventyx Biosciences Begins Phase 2a Trial for VTX3232 Ventyx Biosciences, Inc. (Nasdaq: VTYX), a company focused on creating innovative oral treatments for various inflammatory diseases, has announced the start of dosing for its Phase 2a clinical trial of VTX3232. This important trial is centered on individuals who have been diagnosed with the early stages of Parkinson’s...

Continue Reading